Publications and Presentations

Presentation at the 2023 ESMO Congress

AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors.

Presentation at the 2022 SITC Annual Meeting

Systemic administration of AXA-042, a novel TLR2/6 agonist, reshapes the tumor microenvironment, as revealed by single cell sequencing analysis

Presentation at the 2022 AACR Annual Meeting

AXA-042 – a novel systemic TLR2/6 agonist for anti-tumor therapy